Collectively, these findings identify KIAA1429 as a critical m6A-dependent post-transcriptional regulator of MYC and nominate the KIAA1429-MYC regulatory axis as a promising therapeutic target in ccRCC. Here, MYC is linked to nonpapillary renal cell carcinoma.